Log in to search using one of your social media accounts:

 

AstraZeneca lung cancer drug given green light in US

FDA approval of Tagrisso offers major boost for British company, seeking to release six new cancer medicines by 2020A new lung cancer pill from AstraZeneca has been approved by US regulators, in a major boost for the British drugmaker.AZD9291, which will be sold as Tagrisso, is for advanced non-small-cell lung cancer, the most common form of lung cancer. Tagrisso targets a genetic mutation, known as T790M, that helps tumours evade current lung cancer pills. The drug will be made available to patients in the US as soon as possible and its price will be “comparable to other oral cancer therapies,” a spokeswoman said. AstraZeneca will reveal the price early next week. Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Business Pharmaceuticals industry Cancer Health Society Medical research Source Type: news

Related Links:

This article is protected by copyright. All rights reserved. PMID: 29758087 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Abstract A rapid and sensitive LC-MS/MS method for therapeutic drug monitoring oral vinorelbine (VRL) metronomic anticancer chemotherapy has been developed and validated. Analysis of VRL and its main active metabolite 4-O-deacetylvinorelbine (M1) was performed in whole blood matrix. Both analytes were extracted by protein precipitation and separated on an Onyx monolith C18, 50 x 2 mm column then quantified by positive electrospray ionization and multiple reaction monitoring mode. The LLOQ was 0.05 ng/mL for both VRL and M1. Linearity was up to 25 ng/mL with R2 ≥ 0.994. The intra- and inter-assay precision was &...
Source: Biomedical Chromatography : BMC - Category: Biomedical Science Authors: Tags: Biomed Chromatogr Source Type: research
We sought to compare the toxicity and efficacy of stereotactic body radiotherapy (SBRT) versus stereotactic body proton therapy (SBPT) for high-risk medically inoperable early-stage non-small cell lung cancer (NSCLC).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Immune checkpoint inhibitors (ICIs) are commonly used for treatment of advanced stage non-small cell lung cancer (NSCLC) and numerous clinical studies are examining combinations of ICIs with radiotherapy (RT). Standard-of-care response assessment is CT imaging, which is typically performed no earlier than 2-3 months after treatment initiation due to delayed radiographic responses and occasional pseudoprogression. Improved methods of response assessment would be useful clinically and in trials combining ICIs and RT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Optimal treatment selection for clinical Stage I non-small cell lung cancer (NSCLC) patients currently involves consideration of an individual ’s comorbidities and functional status. Pre-treatment quality of life (QoL) data for this population has been limited. Our goal was to prospectively compare pre-treatment QoL outcomes between Stage I NSCLC patients receiving either stereotactic body radiation therapy (SBRT) or surgical resection, as QoL may correlate with patient satisfaction and post-treatment outcomes.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Rationale: Acute thrombosis has not been reported in the literature so far in lung cancer patients as an immune-related adverse event (irAE) associated with PD-1 pathway inhibitors. Patients concerns: Here, we for the first time present two NSCLC (non-small cell lung cancer) patients suffering from acute thrombosis as a pembrolizumab-induced irAE. Immediate treatment with continuous heparin infusion improved their symptoms and enabled them to continue pembrolizumab administration. Methods: Ethical approval was given by the ethics committee of Osaka International Cancer Institute and the informed consents were given...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
ConclusionThis combined regimen shows efficacy and a manageable safety profile. PFS and OS outcomes are encouraging and warrant further research.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Date: April 23, 2018 Issue #:  1545Summary:  The FDA has approved brigatinib (Alunbrig– Takeda), an oral tyrosine kinase inhibitor, for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib(Xalkori). Translocations of the ALK gene are found in about 5% of lung cancers; they occur predominantly in nonsmokers with adenocarcinoma. Brigatinib is the third tyrosine kinase inhibitor to be approved for this indication; ceritinib(Zykadia) and alectinib(Alecensa) were approved earlie...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research
Gefitinib is an oral tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) for non-small-cell lung cancer with EGFR mutations. Although a few studies have analyzed the causes of gefitinib-induced hepatotoxicity, research focusing on the time intervals before and after hepatotoxicity has yet to be reported. Therefore, this study investigated two types of factors: the time to reach gefitinib-induced hepatotoxicity and the time for recovery. From January 2013 to December 2014, a retrospective study was carried out on 473 non-small-cell lung cancer patients who were treated with gefitinib. The followi...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research | Science